AZILSARTAN MEDOXOMIL (azilsartan kamedoxomil) by R-Pharm US is regulation. Approved for hypertension, to lower blood pressure: in patients not adequately controlled with monotherapy ( ), nonfatal cardiovascular events and 6 more indications. First approved in 2022.
Drug data last refreshed 22h ago
regulation. Azilsartan medoxomil Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principle pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of…
Worked on AZILSARTAN MEDOXOMIL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension